NCT05919680 - A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD). | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 15, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions

Intestinal Failure Associated Liver Disease

Interventions

DRUG

NST-6179 Part A

Once daily (QD) oral administration of 800mg (32 mL solution) of NST-6179 for 4 weeks

DRUG

NST-6179 Part B

Once daily (QD) oral administration of 1200mg of NST-6179 for 12 weeks

OTHER

Matched Placebo

Matched placebo for administration in Part A or Part B

Trial Locations (13)

10029

RECRUITING

Mount Sinai Medical Center, New York

20007

NOT_YET_RECRUITING

MedStar Georgetown University Hospital, Washington D.C.

27710

RECRUITING

Duke University Medical Center, Durham

30322

RECRUITING

Emory University School of Medicine, Atlanta

37232

RECRUITING

Vanderbilt University School of Medicine, Nashville

44195

RECRUITING

The Cleveland Clinic, Cleveland

48202

RECRUITING

Henry Ford Hospital, Detroit

55905

RECRUITING

Mayo Clinic Rochester Campus, Rochester

60637

RECRUITING

The University of Chicago Medical Center, Chicago

85259

RECRUITING

Mayo Clinic Scottsdale Campus, Scottsdale

94143

RECRUITING

University of California San Francisco Medical Center, San Francisco

98195

RECRUITING

University of Washington, Seattle

02115

RECRUITING

Boston Children's Hospital, Boston